O’Leary, S., Yevudza, W. E., Odiase, P., Haider, M. A., Newsome-Cuby, T., Okikioluwa, O., Darko, K., Weiss, H., Barrie, U., Banson, M., & Totimeh, T. (2024). Presentation, management, and outcomes of central nervous system metastases in Africa: Systematic review and meta-analysis. Neuro-Oncology Advances, 7(1). https://doi.org/10.1093/noajnl/vdae219

Odukoya, L. A., Darko, K., Zerd, F., Ghomsi, N. C., Kabare, G., Kamson, D. O., Eckel-Passow, J. E., Jenkins, R. B., Kitange, G. J., Akinjo, A. O., Badmos, K. B., Bankole, O., Idowu, O. E., Karekezi, C., Edrick, E., Ekhator, C., Katasi, V. M., Brown, D. A., Huse, J., … Fonkem, E. (2024). Establishment of a brain tumor consortium of Africa: Advancing collaborative research and advocacy for brain tumors in Africa. Neuro-Oncology Advances, 6(1). https://doi.org/10.1093/noajnl/vdae198

Mendez, J. S., Cohen, A. L., Eckenstein, M., Jensen, R. L., Burt, L. M., Salzman, K. L., Chamberlain, M., Hsu, H. H., Hutchinson, M., Iwamoto, F., Ligon, K. L., Mrugala, M. M., Pelayo, M., Plotkin, S. R., Puduvalli, V. K., Raizer, J., Reardon, D. A., Sterba, M., Walbert, T., … Colman, H. (2024). Phase 1b/2 Study of Orally Administered Pexidartinib in Combination with Radiation Therapy and Temozolomide in Patients with Newly Diagnosed Glioblastoma. Neuro-Oncology Advances. https://doi.org/10.1093/noajnl/vdae202

Yevudza, W. E., Buckman, V., Darko, K., Banson, M., & Totimeh, T. (2024). Neuro-oncology access in Sub-Saharan Africa: A literature review of challenges and opportunities. Neuro-Oncology Advances, 6(1). https://doi.org/10.1093/noajnl/vdae057

Galbraith, K., Vasudevaraja, V., Serrano, J., Shen, G., Tran, I., Abdallat, N., Wen, M., Patel, S., Movahed-Ezazi, M., Faustin, A., Spino-Keeton, M., Roberts, L. G., Maloku, E., Drexler, S. A., Liechty, B. L., Pisapia, D., Krasnozhen-Ratush, O., Rosenblum, M., Shroff, S., … Snuderl, M. (2023). Clinical utility of whole-genome DNA methylation profiling as a primary molecular diagnostic assay for central nervous system tumors—A prospective study and guidelines for clinical testing. Neuro-Oncology Advances, 5(1). https://doi.org/10.1093/noajnl/vdad076

Sperring, C. P., Argenziano, M. G., Savage, W. M., Teasley, D. E., Upadhyayula, P. S., Winans, N. J., Canoll, P., & Bruce, J. N. (2023). Convection-enhanced delivery of immunomodulatory therapy for high-grade glioma. Neuro-Oncology Advances, 5(1). https://doi.org/10.1093/noajnl/vdad044

Picca, A., Di Stefano, A. L., Savatovsky, J., Ducray, F., Chinot, O., Moyal, E. C.-J., Augereau, P., Le Rhun, E., Schmitt, Y., Rousseaux, N., Yepnang, A. M. M., Estellat, C., Charbonneau, F., Letourneur, Q., Branger, D. F., Meyronet, D., Fardeau, C., Mokhtari, K., Bielle, F., … Sanson, M. (2024). TARGET: A phase I/II open-label multicenter study to assess safety and efficacy of fexagratinib in patients with relapsed/refractory FGFR fusion-positive glioma. Neuro-Oncology Advances, 6(1). https://doi.org/10.1093/noajnl/vdae068

Arakawa, Y., Goldlust, S. A., Colman, H., Reardon, D. A., Welch, M. R., Yamaguchi, S., Butowski, N. A., Li, J., Iino, S., Song, G., Jackman, A., Xie, Y., Wagle, M.-C., Lebedinsky, C., & Narita, Y. (2023). 10007-ACT-2 FIRST IN HUMAN STUDY OF DSP-0390, AN ORAL EMOPAMIL BINDING PROTEIN (EBP) INHIBITOR, IN RECURRENT HIGH-GRADE GLIOMA (HGG): PRELIMINARY RESULTS. Neuro-Oncology Advances, 5(Supplement_5), v2–v2. https://doi.org/10.1093/noajnl/vdad141.006

Carneiro, B. A., Papadopoulos, K. P., Strickler, J. H., Lassman, A. B., Waqar, S. N., Chae, Y. K., Patel, J. D., Shacham-Shmueli, E., Kelly, K., Khasraw, M., Bestvina, C. M., Merrell, R., Huang, K., Atluri, H., Ansell, P., Li, R., Jin, J., Anderson, M. G., Reilly, E. B., … Gan, H. K. (2022). Phase I study of anti-epidermal growth factor receptor antibody-drug conjugate serclutamab talirine: Safety, pharmacokinetics, and antitumor activity in advanced glioblastoma. Neuro-Oncology Advances, 5(1). https://doi.org/10.1093/noajnl/vdac183

Svensson, S. F., Halldórsson, S., Latysheva, A., Fuster-Garcia, E., Hjørnevik, T., Fraser-Green, J., Birkeland Bugge, R. A., Grinband, J., Holm, S., Sinkus, R., Vik-Mo, E. O., & Emblem, K. E. (2023). MR elastography identifies regions of extracellular matrix reorganization associated with shorter survival in glioblastoma patients. Neuro-Oncology Advances, 5(1). https://doi.org/10.1093/noajnl/vdad021

Arrillaga-Romany, I., Kurz, S., Tarapore, R., Lu, G., Sumrall, A., Butowski, N., Harrison, R., DeGroot, J., Chi, A., Shonka, N., Umemura, Y., Odia, Y., Mehta, M., Nghiemphu, P., Cloughesy, T., Taylor, L., Graber, J., Kilburn, L., Dixit, K., … Wen, P. (2022). SYST-14 CLINICAL EFFICACY OF ONC201 IN RECURRENT H3 K27M-MUTANT DIFFUSE MIDLINE GLIOMA (DMG) PATIENTS. Neuro-Oncology Advances, 4(Supplement_1), i24–i24. https://doi.org/10.1093/noajnl/vdac078.093

Rubens, J. A., Erker, C., Lindsay, H., Ho, B., Li, B., Bouffet, E., Cohen, A., Eberhart, C., Ertl-Wagner, B., Mahajan, A., Zacharoulis, S., Huang, A., & Packer, R. (2022). Infantile suprasellar tumor diagnosed as a pineoblastoma RB1 subgroup and treatment challenges: A pediatric SNO Molecular Tumor Board. Neuro-Oncology Advances, 4(1). https://doi.org/10.1093/noajnl/vdac092

Kumthekar, P., Grimm, S. A., Aleman, R. T., Chamberlain, M. C., Schiff, D., Wen, P. Y., Iwamoto, F. M., Gursel, D. B., Reardon, D. A., Purow, B., Kocherginski, M., Helenowski, I., & Raizer, J. J. (2022). A multi-institutional phase II trial of bevacizumab for recurrent and refractory meningioma. Neuro-Oncology Advances, 4(1). https://doi.org/10.1093/noajnl/vdac123

Griguer, C. E., Oliva, C. R., Coffey, C. S., Cudkowicz, M. E., Conwit, R. A., Gudjonsdottir, A. L., Ecklund, D. J., Fedler, J. K., Neill-Hudson, T. M., Nabors, L. B., Benge, M., Hackney, J. R., Chase, M., Leonard, T. P., Patel, T., Colman, H., de la Fuente, M., Chaudhary, R., Marder, K., … Markert, J. (2021). Prospective biomarker study in newly diagnosed glioblastoma: Cyto-C clinical trial. Neuro-Oncology Advances, 4(1). https://doi.org/10.1093/noajnl/vdab186